BIOS/UEFI vulnerabilities in the iSeq 100 DNA sequencer from U.S. biotechnology company Illumina could let attackers disable devices used for detecting illnesses and developing vaccines. The ...

BIOS/UEFI vulnerabilities in the iSeq 100 DNA sequencer from U.S. biotechnology company Illumina could let attackers disable devices used for detecting illnesses and developing vaccines.

Eclypsium security researchers have uncovered UEFI vulnerabilities in the Illumina iSeq 100 DNA sequencer, but the broader issue involves the device development process at large. In highlighting ...

On Tuesday, researchers from firmware security firm Eclypsium called out one of them: the Illumina iSeq 100, a DNA sequencer that's a staple at 23andMe and thousands of other gene-sequencing ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that ...

Argentine cybersecurity shop Eclypsium claims security issues affecting leading DNA sequencing devices could lead to disruptions in crucial clinical research.… The iSeq 100, developed by ...

Researchers from Eclypsium find vulnerability in the way iSeq 100 boots up The bug allows threat actors to establish persistence, brick the device, or tamper with the results A patch has since ...

Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,715.56 today based on a price of $138.05 for ILMN at the time of writing.

The Iseq rose by 0.1 per cent; London’s FTSE 100 was up 0.3 per cent; the Dax saw a 0.1 per cent rise ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

Currently, Illumina has a market capitalization of $22.18 billion. Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $3,290.99 today based on a ...